TB-500: Mechanism, Research, and Storage

TB-500 occupies an unusual position in the research peptide landscape: widely studied, commercially common, and frequently mislabeled. The compound’s parent molecule — Thymosin Beta-4, or TB-4 — has been the subject of substantial preclinical research for decades, including high-profile work in cardiac repair and wound healing. But many products sold as “TB-500” actually contain full-length TB-4 rather than the 7-amino-acid fragment the name implies. The distinction matters for how research findings translate from one to the other. This guide examines TB-500 as researchers should: as a specific synthetic fragment with a defined mechanism, a particular position relative to its parent peptide, and a set of research applications that the literature actually supports.

Below, we cover TB-500’s structural origins, mechanism of action, the four research domains where it has been most actively studied, and the reconstitution and storage considerations researchers should understand before working with the compound.

What Is TB-500?

TB-500 is a synthetic 7-amino-acid peptide with the sequence Ac-LKKTETQ. The N-terminus is acetylated, which extends biological stability. The fragment corresponds to the active actin-binding region of Thymosin Beta-4 (TB-4), a 44-amino-acid peptide that occurs naturally in nearly all human cells. TB-4 is particularly concentrated in platelets and white blood cells, where it was first isolated and characterized in the early 1980s.

The molecular weight of the TB-500 fragment is approximately 888 Da. TB-4, the parent peptide, has a molecular weight closer to 4,963 Da — substantially larger. This size difference is the most reliable analytical marker for distinguishing the two: mass spectrometry of a product labeled “TB-500” should return a peak consistent with the fragment, not the parent.

In research contexts, “TB-500” and “Thymosin Beta-4” are often used interchangeably, but the two are chemically distinct molecules with different biological half-lives, different administration considerations, and somewhat different research literatures. When evaluating findings reported as “TB-500 research,” it is worth checking which molecule was actually used.

Both TB-500 and TB-4 are produced synthetically for laboratory research purposes. Neither is approved for human therapeutic use by any regulatory agency.

Mechanism of Action

TB-500’s primary mechanism is actin sequestration. The peptide binds monomeric G-actin and regulates the dynamic equilibrium between G-actin and filamentous F-actin polymerization [Ref. 1]. This regulation underlies the broader effects observed across the TB-4 and TB-500 research literatures: cell migration, proliferation, anti-apoptotic activity, and tissue repair all depend on coordinated actin reorganization.

A landmark 2007 paper by Smart and colleagues in Nature demonstrated that TB-4 promotes epicardial progenitor cell mobilization and neovascularization in cardiac repair models — mechanistically linking actin reorganization to cardiac stem cell behavior [Ref. 2]. A separate body of work by Bock-Marquette and colleagues, also in Nature, identified TB-4’s role in activating integrin-linked kinase, which contributes to cardiac cell migration and survival [Ref. 3].

Beyond direct actin binding, TB-500 and TB-4 influence several secondary pathways.

Anti-inflammatory activity. TB-4 modulates inflammatory cytokine production and has been studied in models of acute inflammation, autoimmune injury, and wound-site inflammation.

Anti-apoptotic effects. Cells exposed to TB-4 show reduced apoptotic signaling in injury contexts, contributing to the compound’s tissue-protective profile.

Angiogenesis. TB-4 promotes endothelial cell migration and vascular remodeling. Unlike BPC-157, which acts through direct VEGFR2 receptor upregulation, TB-4’s angiogenic effects appear to be downstream of cytoskeletal reorganization in endothelial cells.

Cell migration broadly. The combined effects of actin regulation, anti-apoptosis, and chemotactic signaling make TB-4 a notable promoter of cell migration in wound and injury models.

For a mechanism-by-mechanism comparison with a related tissue-repair compound, see our BPC-157 vs TB-500 Research Comparison.

Research Applications

Preclinical research on TB-500 and TB-4 clusters into four primary domains.

Cardiac repair

This is TB-4’s most well-developed research domain. Studies have examined cardiomyocyte migration following infarction, epicardial progenitor cell mobilization, and cardiac vessel formation in ischemic injury models. The Smart 2007 and Bock-Marquette 2004 Nature papers established this research direction; subsequent work has explored timing, dosing, and combination protocols across multiple injury models.

Wound healing

TB-4 has substantial wound healing literature, including dermal, corneal, and oral mucosa models. Malinda and colleagues demonstrated that TB-4 accelerates dermal wound closure [Ref. 4]. Sosne and colleagues established corneal wound healing as a particular strength of the compound, with multiple studies on epithelial regeneration following alkali burn and other injury models. A 2016 review by Kleinman and Sosne in Vitamins and Hormones synthesizes the dermal healing literature [Ref. 5].

Tissue migration and stem cell research

Because actin regulation is fundamental to cell migration, TB-4 has been used in research examining mesenchymal stem cell behavior, immune cell trafficking, and progenitor cell mobilization across multiple tissue contexts. A comprehensive 2012 review by Goldstein and colleagues in Expert Opinion on Biological Therapy covers TB-4’s role across these regenerative applications [Ref. 6].

Inflammation and immune modulation

Studies have examined TB-4’s effects in models of acute and chronic inflammation, including septic injury, autoimmune contexts, and post-surgical inflammation. The anti-inflammatory effects are mechanistically tied to actin reorganization in immune cells and to direct modulation of inflammatory cytokines.

Across all four domains, the same caveat applies: TB-500 and TB-4 have not been approved for human therapeutic use. Research findings are preclinical and should not be interpreted as evidence of human safety or efficacy.

Dosing & Reconstitution for Research

Researchers working with lyophilized TB-500 must reconstitute the compound with bacteriostatic water before use. The math follows the same concentration-equals-mass-divided-by-volume principle as other research peptides.

A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. A 10 mg vial in 2 mL yields 5 mg/mL. Choice of dilution volume depends on the precision of the syringe and the volume per aliquot the protocol calls for.

Two TB-500-specific considerations deserve particular attention.

The fragment-versus-full-length distinction affects molar concentration calculations. A 5 mg vial of TB-500 (the 7-amino-acid fragment) contains approximately 5.6 µmol of peptide. A 5 mg vial of full-length TB-4 contains approximately 1.0 µmol — almost six times fewer molecules. If a research protocol cites a target concentration in molar terms (nmol/mL or µmol/mL), the choice of fragment versus full-length materially changes the dose. Always confirm which molecule is in the vial by checking the molecular weight on the Certificate of Analysis.

Reconstitution should be slow and gentle. Inject bacteriostatic water down the inner wall of the vial rather than directly onto the lyophilized powder. Direct injection can cause foaming and complicate accurate concentration measurement. Swirl gently — do not shake — until fully dissolved.

Researchers can verify their concentration math against our peptide reconstitution calculator, which handles the conversion automatically and accounts for target concentration, dilution volume, and syringe unit markings.

Storage & Handling

Lyophilized TB-500 is stable at room temperature during shipping but should be moved to long-term storage at -20°C (-4°F), protected from light, on receipt. Under proper lyophilized conditions, the compound remains stable for 24 months or longer.

Once reconstituted, TB-500 should be stored at 2–8°C and used within 28 days. The acetylated N-terminus provides some additional stability compared to non-acetylated short peptide fragments, but does not eliminate the need for proper cold storage. Repeated freeze-thaw cycles degrade peptide integrity and should be avoided.

Researchers planning to draw from a reconstituted vial across multiple sessions should consider aliquoting into smaller volumes immediately after reconstitution to minimize freeze-thaw exposure of the working stock.

Every vial should be visually inspected before use. The reconstituted solution should be clear and free of particulates. Cloudiness, discoloration, or visible sediment indicates degradation, and the vial should not be used in research.

For full handling protocols across the broader peptide catalog, see our storage and reconstitution guide.

Sourcing Verified TB-500 for Research

Peptide quality verification matters more for TB-500 than for most other research peptides because of the fragment-versus-full-length mislabeling problem. Independent testing data from grey-market suppliers consistently reveals products labeled “TB-500” that contain full-length Thymosin Beta-4 — a different molecule with different research characteristics, different molar dosing implications, and a different research literature.

A credible Certificate of Analysis for TB-500 should show three things at minimum: HPLC purity expressed as a percentage, mass spectrometry confirmation matching the 7-amino-acid fragment’s molecular weight (approximately 888 Da, not approximately 4,963 Da), and a clear distinction between peptide content and peptide mass.

Kinetic Compounds publishes the full Certificate of Analysis for every batch of TB-500, with all testing performed by Janoshik Analytical, an independent third-party laboratory. Researchers can review the current batch report on the TB-500 product page, and our broader testing methodology is documented on our lab testing and COA page.

For researchers running combination protocols with BPC-157, our BPC-157 + TB-500 Blend ships both peptides with COA data covering both compounds. The full healing and recovery research peptide catalog lists all related compounds.

CTA (place at end of article body, before References)
Running combination research protocols? Our pre-blended BPC-157 + TB-500 product ships both peptides in a single vial with full analytical documentation covering both compounds → View the BPC-157 + TB-500 Blend